8 completed. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow Allergic Rhinoconjunctivitis: new trials by email Literature Review of Allergic Rhinoconjunctivitis trials Research Report on Allergic Rhinoconjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen BM41, Placebo, ALK Alutard SQ Betula verrucosa - Birch Pollen Allergy, Allergic Rhinoconjunctivitis | Phase 1 | Completed | Odense University Hospital | 47 | 2018-09-17 | 2023-12-11 |
| Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites Allergovac depot DPT/DF (50:50) - Allergic Rhinoconjunctivitis | Phase 1 | Completed | Roxall Medicina España S.A | 43 | 2016-07-01 | 2017-10-20 |
| MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009) MK-8237, Placebo, NAC - Allergic Rhinitis, Allergic Rhinoconjunctivitis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 26 | 2013-11-27 | 2019-03-15 |
| A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection - Allergic Rhinoconjunctivitis | Phase 1 | Completed | Immunomic Therapeutics, Inc. | 17 | 2013-09-01 | 2014-04-30 |
| A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection - Allergic Rhinoconjunctivitis | Phase 1 | Completed | Immunomic Therapeutics, Inc. | 24 | 2012-10-01 | 2014-05-22 |
| Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT) subcutaneous immunotherapy with DPT extract, Subcutaneous depot placebo - Allergic Rhinoconjunctivitis | Phase 1 | Completed | Roxall Medicina España S.A | 48 | 2011-01-01 | 2019-05-06 |
| Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense Subcutaneous immunotherapy with Phleum pratense pollen extract - Allergic Rhinoconjunctivitis | Phase 1 | Completed | Roxall Medicina España S.A | 42 | 2010-01-01 | 2017-05-01 |
| Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) Bilastine - Allergic Rhinoconjunctivitis, Chronic Urticaria | Phase 1 / Phase 2 | Completed | Faes Farma, S.A. | 36 | 2010-01-01 | 2012-09-26 |
Rhinitis, Allergic (3) · Hypersensitivity (2) · Chronic Urticaria (1) · Erythema (1) · Nasal Obstruction (1) · Pruritus (1) · Rhinitis, Allergic, Perennial (1) · Rhinitis, Allergic, Seasonal (1) · Rhinorrhea (1) · Sneezing (1) · Urticaria (1)
Immune System Diseases (4) · Hypersensitivity, Immediate (3) · Nose Diseases (3) · Otorhinolaryngologic Diseases (3) · Respiratory Hypersensitivity (3) · Respiratory Tract Diseases (3) · Rhinitis (3) · Hypersensitivity (2) · Airway Obstruction (1) · Chronic Disease (1) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1) · Respiratory Insufficiency (1)
bilastine (1)
Roxall Medicina España S.A (3) · Immunomic Therapeutics, Inc. (2) · Faes Farma, S.A. (1) · Merck Sharp & Dohme LLC (1) · Odense University Hospital (1)
Spain (3) · United States (2) · Australia (1) · Denmark (1) · Germany (1) · Sweden (1)
David Fitz-Patrick, MD (2) · Araitz Landeta (1) · Carsten Bindslev-Jensen, Professor (1) · Gunilla Hedlin, Prof. Dr. (1) · Lennart Nordvall, Prof. Dr (1) · Noel E Cranswick, Prof. Dr. (1) · Peter Le Souef, Prof. Dr. (1) · Stefan Zielen, Prof. Dr. (1) · Ulrich Wahn, Prof. Dr. (1)
2009 (3), 2018 (1)